Edwards Lifesciences (EW) Price & Analysis

Compare

1,920 Followers

EW Stock Chart & Stats

$86.23

$0.80(1.09%)

At close: Jan 08 4:00 PM EST

$86.23

$0.80(1.09%)

Day’s Range― - ―

52-Week Range$65.94 - $87.89

Previous CloseN/A

Volume821.68K

Average Volume (3M)3.42M

Market Cap

$50.04B

Enterprise Value$42.41B

Total Cash (Recent Filing)$3.84B

Total Debt (Recent Filing)$700.30M

Price to Earnings (P/E)36.7

Beta0.67

Next Earnings

Feb 04, 2026

EPS Estimate

0.62

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.67

Shares Outstanding580,300,000

10 Day Avg. Volume3,615,393

30 Day Avg. Volume3,423,329

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)4.43

Price to Sales (P/S)8.13

P/FCF Ratio152.63

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue7.21

Enterprise Value/Gross Profit9.21

Enterprise Value/Ebitda24.34

Forecast

1Y Price Target

$95.86

Price Target Upside11.17% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering24

EPS Forecast (FY)2.6

Revenue Forecast (FY)$6.04B

Bulls Say, Bears Say

Bulls Say

Market ExpansionRecent guideline revisions and the performance of TAVR in asymptomatic patients could expand the eligible pool of candidates dramatically, reframing the therapy as preventive rather than reactive care.

Product LaunchesExpected launches of new products like Sapien M3 and Pascal TR in the US are poised to drive future growth for Edwards Lifesciences.

Revenue GrowthThe company is guiding to 6-8% TAVR growth and 8-10% total revenue growth, indicating strong future performance.

Bears Say

Operational BarriersHospital and operator volume criteria pose barriers for hospitals in under-resourced areas, limiting the initiation or maintenance of TAVR programs.

Regulatory ChallengesCurrent NCD restrictions are impacting TAVR treatments, leaving a significant number of diagnosed symptomatic patients untreated, which highlights the need for less restrictive policies.

Treatment DelaysCurrent NCD restrictions have led to significant delays in treatment for symptomatic patients, indicating the need for less restrictive policies to improve patient outcomes.

Edwards Lifesciences News

Edwards Lifesciences receives FDA approval for SAPIEN M3 mitral valve system

Edwards Lifesciences (EW) announced its SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a...

3d ago

Edwards Lifesciences upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Edwards Lifesciences (EW) to Overweight from Neutral with a price target of $100, up from $90....

8d ago

Edwards Lifesciences price target lowered to $87 from $89 at Canaccord

Canaccord analyst William Plovanic lowered the firm’s price target on Edwards Lifesciences (EW) to $87 from $89 and...

9d ago

Edwards Lifesciences price target lowered to $87 from $88 at Baird

Baird analyst David Rescott lowered the firm’s price target on Edwards Lifesciences (EW) to $87 from $88 and...

10d ago

Edwards Lifesciences price target raised to $101 from $96 at Citi

Citi analyst Joanne Wuensch raised the firm’s price target on Edwards Lifesciences (EW) to $101 from $96 and...

15d ago

Edwards Lifesciences price target raised to $103 from $99 at Barclays

Barclays raised the firm’s price target on Edwards Lifesciences (EW) to $103 from $99 and keeps an Overweight...

18d ago

Edwards Lifesciences price target raised to $100 from $95 at RBC Capital

RBC Capital analyst Shagun Singh raised the firm’s price target on Edwards Lifesciences (EW) to $100 from $95...

21d ago

Edwards Lifesciences price target raised to $92 from $90 at Truist

Truist raised the firm’s price target on Edwards Lifesciences (EW) to $92 from $90 and keeps a Hold...

21d ago

Edwards Lifesciences price target raised to $92 from $90 at UBS

UBS raised the firm’s price target on Edwards Lifesciences (EW) to $92 from $90 and keeps a Neutral...

21d ago

Edwards Lifesciences price target raised to $88 from $83 at Baird

Baird analyst David Rescott raised the firm’s price target on Edwards Lifesciences (EW) to $88 from $83 and...

21d ago

Edwards Lifesciences Advances Smart Surgery Monitoring With Completed SMART TRENDS Study

Edwards Lifesciences Corp. ($EW) announced an update on their ongoing clinical study. Study OverviewThe “SMART TRENDS Study,” officially...

4d ago

Edwards Lifesciences: Buy Rating on Structural Heart Leadership, Accelerating TAVR/TMTT Growth, and Durable Double‑Digit Upside

Edwards Lifesciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robbie Marcus from...

8d ago

Positive Outlook for Edwards Lifesciences Amid CMS Coverage Expansion for TAVR Procedures

William Blair analyst Brandon Vazquez has reiterated their bullish stance on EW stock, giving a Buy rating today....

10d ago

Buy Rating for Edwards Lifesciences Amid Potential TAVR Coverage Expansion and Strategic Alignment

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Edwards Lifesciences. The associated price target remains...

10d ago

EW FAQ

What was Edwards Lifesciences’s price range in the past 12 months?

Edwards Lifesciences lowest stock price was $65.94 and its highest was $87.89 in the past 12 months.

What is Edwards Lifesciences’s market cap?

Edwards Lifesciences’s market cap is $50.04B.

When is Edwards Lifesciences’s upcoming earnings report date?

Edwards Lifesciences’s upcoming earnings report date is Feb 04, 2026 which is in 40 days.

How were Edwards Lifesciences’s earnings last quarter?

Edwards Lifesciences released its earnings results on Oct 30, 2025. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.596 by $0.074.

Is Edwards Lifesciences overvalued?

According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Edwards Lifesciences pay dividends?

Edwards Lifesciences does not currently pay dividends.

What is Edwards Lifesciences’s EPS estimate?

Edwards Lifesciences’s EPS estimate is 0.62.

How many shares outstanding does Edwards Lifesciences have?

Edwards Lifesciences has 580,300,000 shares outstanding.

What happened to Edwards Lifesciences’s price movement after its last earnings report?

Edwards Lifesciences reported an EPS of $0.67 in its last earnings report, beating expectations of $0.596. Following the earnings report the stock price went down -1.234%.

Which hedge fund is a major shareholder of Edwards Lifesciences?

Currently, no hedge funds are holding shares in EW

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Edwards Lifesciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

13.59%

Trailing 12-Months

Asset Growth

2.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences (EW) Earnings & Revenues

Historic Earnings Reports

EW Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Edwards Lifesciences reported strong quarterly performance with significant sales growth across multiple segments, increased full-year guidance, and positive clinical data presentations. However, there were some concerns about declining gross profit margins and upcoming changes in financial leadership.View all EW earnings summaries

EW Net sales Breakdown

75.49% Transcatheter Aortic Valve Replacement

6.47% Transcatheter Mitral and Tricuspid Therapies

18.04% Surgical Structural Heart

EW Stock 12 Month Forecast

Average Price Target

$95.86

▲(11.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"69":"$69","78":"$78","87":"$87","96":"$96","105":"$105"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$104.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$95.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$84.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[69,78,87,96,105],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.27,86.71076923076923,88.15153846153846,89.59230769230768,91.03307692307692,92.47384615384615,93.91461538461539,95.35538461538461,96.79615384615384,98.23692307692308,99.67769230769231,101.11846153846153,102.55923076923077,{"y":104,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.27,86.08461538461538,86.89923076923077,87.71384615384615,88.52846153846154,89.34307692307692,90.1576923076923,90.9723076923077,91.78692307692307,92.60153846153845,93.41615384615385,94.23076923076923,95.04538461538462,{"y":95.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.27,85.17230769230768,85.07461538461538,84.97692307692307,84.87923076923077,84.78153846153846,84.68384615384615,84.58615384615385,84.48846153846154,84.39076923076922,84.29307692307692,84.19538461538461,84.09769230769231,{"y":84,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":70.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.45,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >